Ventilator Associated Pneumonia (VAP) - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：88頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Ventilator Associated Pneumonia (VAP) - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Ventilator Associated Pneumonia (VAP) - Pipeline Review, H1 2014’, provides an overview of the Ventilator Associated Pneumonia (VAP)’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Ventilator Associated Pneumonia (VAP), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ventilator Associated Pneumonia (VAP) and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Ventilator Associated Pneumonia (VAP)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Ventilator Associated Pneumonia (VAP) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Ventilator Associated Pneumonia (VAP) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Ventilator Associated Pneumonia (VAP) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Ventilator Associated Pneumonia (VAP)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Ventilator Associated Pneumonia (VAP) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Ventilator Associated Pneumonia (VAP) - Pipeline Review, H1 2014’, provides an overview of the Ventilator Associated Pneumonia (VAP)’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Ventilator Associated Pneumonia (VAP), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ventilator Associated Pneumonia (VAP) and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Ventilator Associated Pneumonia (VAP)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Ventilator Associated Pneumonia (VAP) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Ventilator Associated Pneumonia (VAP) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Ventilator Associated Pneumonia (VAP) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Ventilator Associated Pneumonia (VAP)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Ventilator Associated Pneumonia (VAP) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Ventilator Associated Pneumonia (VAP) Overview 8
Therapeutics Development 9
Pipeline Products for Ventilator Associated Pneumonia (VAP) - Overview 9
Pipeline Products for Ventilator Associated Pneumonia (VAP) - Comparative Analysis 10
Ventilator Associated Pneumonia (VAP) - Therapeutics under Development by Companies 11
Ventilator Associated Pneumonia (VAP) - Therapeutics under Investigation by Universities/Institutes 13
Ventilator Associated Pneumonia (VAP) - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Ventilator Associated Pneumonia (VAP) - Products under Development by Companies 17
Ventilator Associated Pneumonia (VAP) - Products under Investigation by Universities/Institutes 18
Ventilator Associated Pneumonia (VAP) - Companies Involved in Therapeutics Development 19
AstraZeneca PLC 19
Cubist Pharmaceuticals, Inc. 20
Paratek Pharmaceuticals, Inc. 21
Aridis Pharmaceuticals LLC 22
KaloBios Pharmaceuticals, Inc. 23
Tetraphase Pharmaceuticals Inc. 24
Savara Inc. 25
Cardeas Pharma Corp. 26
Meiji Seika Pharma Co., Ltd. 27
Biota Pharmaceuticals, Inc. 28
Adenium Biotech ApS 29
Serendex Pharmaceuticals A/S 30
Dong-A Socio Holdings Co Ltd 31
Ventilator Associated Pneumonia (VAP) - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Combination Products 33
Assessment by Target 34
Assessment by Mechanism of Action 37
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
tedizolid phosphate - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
(ceftazidime + avibactam) - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
simvastatin - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
panobacumab - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
(ceftolozane + tazobactam) - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
eravacycline - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
(amikacin + fosfomycin) - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
KB-001-A - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
arbekacin - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
MAR Program - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
vancomycin - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
PopB-Based Vaccine - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Pseudomonas aeruginosa Vaccine - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
GyrB/ParE Antibiotic - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
AA-139 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
fosfomycin - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
sargramostim - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Ventilator Associated Pneumonia (VAP) - Recent Pipeline Updates 67
Ventilator Associated Pneumonia (VAP) - Dormant Projects 83
Ventilator Associated Pneumonia (VAP) - Discontinued Products 84
Ventilator Associated Pneumonia (VAP) - Product Development Milestones 85
Featured News & Press Releases 85
Jun 21, 2013: Theravance Gets FDA Approval For Vibativ For Treatment Of Hospital-Acquired And Ventilator-Associated Bacterial Pneumonia 85
May 07, 2013: Cubist’s Late-stage Antibiotic Candidate CXA-201 Receives FDA Fast Track Designation 85
Appendix 87
Methodology 87
Coverage 87
Secondary Research 87
Primary Research 87
Expert Panel Validation 87
Contact Us 88
Disclaimer 88
List of Tables
Number of Products under Development for Ventilator Associated Pneumonia (VAP), H1 2014 9
Number of Products under Development for Ventilator Associated Pneumonia (VAP) - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Late Stage Development, H1 2014 14
Comparative Analysis by Clinical Stage Development, H1 2014 15
Comparative Analysis by Early Stage Development, H1 2014 16
Products under Development by Companies, H1 2014 17
Products under Investigation by Universities/Institutes, H1 2014 18
Ventilator Associated Pneumonia (VAP) - Pipeline by AstraZeneca PLC, H1 2014 19
Ventilator Associated Pneumonia (VAP) - Pipeline by Cubist Pharmaceuticals, Inc., H1 2014 20
Ventilator Associated Pneumonia (VAP) - Pipeline by Paratek Pharmaceuticals, Inc., H1 2014 21
Ventilator Associated Pneumonia (VAP) - Pipeline by Aridis Pharmaceuticals LLC, H1 2014 22
Ventilator Associated Pneumonia (VAP) - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2014 23
Ventilator Associated Pneumonia (VAP) - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2014 24
Ventilator Associated Pneumonia (VAP) - Pipeline by Savara Inc., H1 2014 25
Ventilator Associated Pneumonia (VAP) - Pipeline by Cardeas Pharma Corp., H1 2014 26
Ventilator Associated Pneumonia (VAP) - Pipeline by Meiji Seika Pharma Co., Ltd., H1 2014 27
Ventilator Associated Pneumonia (VAP) - Pipeline by Biota Pharmaceuticals, Inc., H1 2014 28
Ventilator Associated Pneumonia (VAP) - Pipeline by Adenium Biotech ApS, H1 2014 29
Ventilator Associated Pneumonia (VAP) - Pipeline by Serendex Pharmaceuticals A/S, H1 2014 30
Ventilator Associated Pneumonia (VAP) - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2014 31
Assessment by Monotherapy Products, H1 2014 32
Assessment by Combination Products, H1 2014 33
Number of Products by Stage and Target, H1 2014 36
Number of Products by Stage and Mechanism of Action, H1 2014 39
Number of Products by Stage and Route of Administration, H1 2014 41
Number of Products by Stage and Molecule Type, H1 2014 43
Ventilator Associated Pneumonia (VAP) Therapeutics - Recent Pipeline Updates, H1 2014 67
Ventilator Associated Pneumonia (VAP) - Dormant Projects, H1 2014 83
Ventilator Associated Pneumonia (VAP) - Discontinued Products, H1 2014 84
List of Figures
Number of Products under Development for Ventilator Associated Pneumonia (VAP), H1 2014 9
Number of Products under Development for Ventilator Associated Pneumonia (VAP) - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Late Stage Development, H1 2014 14
Comparative Analysis by Clinical Stage Development, H1 2014 15
Comparative Analysis by Early Stage Products, H1 2014 16
Assessment by Monotherapy Products, H1 2014 32
Assessment by Combination Products, H1 2014 33
Number of Products by Top 10 Target, H1 2014 34
Number of Products by Stage and Top 10 Target, H1 2014 35
Number of Products by Top 10 Mechanism of Action, H1 2014 37
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 38
Number of Products by Top 10 Route of Administration, H1 2014 40
Number of Products by Stage and Top 10 Route of Administration, H1 2014 41
Number of Products by Top 10 Molecule Type, H1 2014 42
Number of Products by Stage and Top 10 Molecule Type, H1 2014 43
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Ventilator Associated Pneumonia (VAP) Overview 8
Therapeutics Development 9
Pipeline Products for Ventilator Associated Pneumonia (VAP) - Overview 9
Pipeline Products for Ventilator Associated Pneumonia (VAP) - Comparative Analysis 10
Ventilator Associated Pneumonia (VAP) - Therapeutics under Development by Companies 11
Ventilator Associated Pneumonia (VAP) - Therapeutics under Investigation by Universities/Institutes 13
Ventilator Associated Pneumonia (VAP) - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Ventilator Associated Pneumonia (VAP) - Products under Development by Companies 17
Ventilator Associated Pneumonia (VAP) - Products under Investigation by Universities/Institutes 18
Ventilator Associated Pneumonia (VAP) - Companies Involved in Therapeutics Development 19
AstraZeneca PLC 19
Cubist Pharmaceuticals, Inc. 20
Paratek Pharmaceuticals, Inc. 21
Aridis Pharmaceuticals LLC 22
KaloBios Pharmaceuticals, Inc. 23
Tetraphase Pharmaceuticals Inc. 24
Savara Inc. 25
Cardeas Pharma Corp. 26
Meiji Seika Pharma Co., Ltd. 27
Biota Pharmaceuticals, Inc. 28
Adenium Biotech ApS 29
Serendex Pharmaceuticals A/S 30
Dong-A Socio Holdings Co Ltd 31
Ventilator Associated Pneumonia (VAP) - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Combination Products 33
Assessment by Target 34
Assessment by Mechanism of Action 37
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
tedizolid phosphate - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
(ceftazidime + avibactam) - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
simvastatin - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
panobacumab - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
(ceftolozane + tazobactam) - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
eravacycline - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
(amikacin + fosfomycin) - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
KB-001-A - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
arbekacin - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
MAR Program - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
vancomycin - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
PopB-Based Vaccine - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Pseudomonas aeruginosa Vaccine - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
GyrB/ParE Antibiotic - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
AA-139 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
fosfomycin - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
sargramostim - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Ventilator Associated Pneumonia (VAP) - Recent Pipeline Updates 67
Ventilator Associated Pneumonia (VAP) - Dormant Projects 83
Ventilator Associated Pneumonia (VAP) - Discontinued Products 84
Ventilator Associated Pneumonia (VAP) - Product Development Milestones 85
Featured News & Press Releases 85
Jun 21, 2013: Theravance Gets FDA Approval For Vibativ For Treatment Of Hospital-Acquired And Ventilator-Associated Bacterial Pneumonia 85
May 07, 2013: Cubist’s Late-stage Antibiotic Candidate CXA-201 Receives FDA Fast Track Designation 85
Appendix 87
Methodology 87
Coverage 87
Secondary Research 87
Primary Research 87
Expert Panel Validation 87
Contact Us 88
Disclaimer 88
List of Tables
Number of Products under Development for Ventilator Associated Pneumonia (VAP), H1 2014 9
Number of Products under Development for Ventilator Associated Pneumonia (VAP) - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Late Stage Development, H1 2014 14
Comparative Analysis by Clinical Stage Development, H1 2014 15
Comparative Analysis by Early Stage Development, H1 2014 16
Products under Development by Companies, H1 2014 17
Products under Investigation by Universities/Institutes, H1 2014 18
Ventilator Associated Pneumonia (VAP) - Pipeline by AstraZeneca PLC, H1 2014 19
Ventilator Associated Pneumonia (VAP) - Pipeline by Cubist Pharmaceuticals, Inc., H1 2014 20
Ventilator Associated Pneumonia (VAP) - Pipeline by Paratek Pharmaceuticals, Inc., H1 2014 21
Ventilator Associated Pneumonia (VAP) - Pipeline by Aridis Pharmaceuticals LLC, H1 2014 22
Ventilator Associated Pneumonia (VAP) - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2014 23
Ventilator Associated Pneumonia (VAP) - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2014 24
Ventilator Associated Pneumonia (VAP) - Pipeline by Savara Inc., H1 2014 25
Ventilator Associated Pneumonia (VAP) - Pipeline by Cardeas Pharma Corp., H1 2014 26
Ventilator Associated Pneumonia (VAP) - Pipeline by Meiji Seika Pharma Co., Ltd., H1 2014 27
Ventilator Associated Pneumonia (VAP) - Pipeline by Biota Pharmaceuticals, Inc., H1 2014 28
Ventilator Associated Pneumonia (VAP) - Pipeline by Adenium Biotech ApS, H1 2014 29
Ventilator Associated Pneumonia (VAP) - Pipeline by Serendex Pharmaceuticals A/S, H1 2014 30
Ventilator Associated Pneumonia (VAP) - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2014 31
Assessment by Monotherapy Products, H1 2014 32
Assessment by Combination Products, H1 2014 33
Number of Products by Stage and Target, H1 2014 36
Number of Products by Stage and Mechanism of Action, H1 2014 39
Number of Products by Stage and Route of Administration, H1 2014 41
Number of Products by Stage and Molecule Type, H1 2014 43
Ventilator Associated Pneumonia (VAP) Therapeutics - Recent Pipeline Updates, H1 2014 67
Ventilator Associated Pneumonia (VAP) - Dormant Projects, H1 2014 83
Ventilator Associated Pneumonia (VAP) - Discontinued Products, H1 2014 84
List of Figures
Number of Products under Development for Ventilator Associated Pneumonia (VAP), H1 2014 9
Number of Products under Development for Ventilator Associated Pneumonia (VAP) - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Late Stage Development, H1 2014 14
Comparative Analysis by Clinical Stage Development, H1 2014 15
Comparative Analysis by Early Stage Products, H1 2014 16
Assessment by Monotherapy Products, H1 2014 32
Assessment by Combination Products, H1 2014 33
Number of Products by Top 10 Target, H1 2014 34
Number of Products by Stage and Top 10 Target, H1 2014 35
Number of Products by Top 10 Mechanism of Action, H1 2014 37
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 38
Number of Products by Top 10 Route of Administration, H1 2014 40
Number of Products by Stage and Top 10 Route of Administration, H1 2014 41
Number of Products by Top 10 Molecule Type, H1 2014 42
Number of Products by Stage and Top 10 Molecule Type, H1 2014 43
